

PHARMACIA CORP /DE/
 Form 5
 February 15, 2002

 OMB APPROVAL

 OMB Number: 323
 Expires: December 31
 Estimated average bu
 hours per response..

FORM 5

- Check box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
- Form 3 Holdings Reported
- Form 4 Transactions Reported

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549

ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker
Hassan	Fred		Pharmacia Corp
(Last)	(First)	(Middle)	3. I.R.S. Identification Number of Reporting Person, if an entity (Voluntary)
100 Route 206 North			
(Street)			
Peapack,	NJ	07977	
(City)	(State)	(Zip)	

6. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

Director
 10% Owner

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

*If the form is filed by more than one reporting person, see Instruction 4(b)(v).

(Over)
SEC 2270 (3-99)

Page 1 of 3

FORM 5 (continued)

Hassan, Fred -- December 2001

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date and Expiration (Mo)
				(A)	(D)	
Option (right to buy)	\$49.10	04/02/2001	A	597,964		(3)
Option (right to buy)	\$49.10	04/02/2001	A	2,036		(4)
Option (right to buy)	\$37.32					(5)
Option (right to buy)	\$51.59					(3)
Option (right to buy)	\$41.23					(5)
Option (right to buy)	\$45.90					(5)
Option (right to buy)	\$33.64					(5)
Option (right to buy)	\$26.89					(5)
Performance Share Units	1-for-1					(6)

7. Title and Amount of 8. Price of 9. Number of 10. Ownership 11. Nature

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

Underlying Securities (Instr. 3 and 4)	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned at End of Year (Instr. 4)	of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	of Indir Benefici Ownersh (Instr.
Title	Amount or Number of Shares			
Common	597,964		D	
Common	2,036	600,000	D	
Common	178,500	178,500	D	
Common	500,000	500,000	D	
Common	416,500	416,500	D	
Common	476,000	476,000	D	
Common	357,000	357,000	D	
Common	595,000	595,000	D	
Common	100,000	100,000	D	

Explanation of Responses:

See attached statement

**Intentional misstatements or omissions of facts constitute Federal Criminal Violations.

See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed.
If space provided is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Don W. Schmitz

** Signature of Reporting Person
Don W. Schmitz, attorney-in-fact for
Fred Hassan

2/14/2002

Date

Page 2
SEC 2270 (3-99)

Page 2 of 3

Edgar Filing: PHARMACIA CORP /DE/ - Form 5

Pharmacia Corporation PHA

Form 5 - December 2001

Hassan, Fred

100 Route 206 North

Peapack, NJ 07977

Explanation of responses:

- (1) Includes 238,000 Restricted Shares
- (2) Includes 1156 shares acquired through company savings plan since last reported to the SEC.
- (3) Option becomes exercisable for one-third of the shares on the first, second and third anniversary of the grant date.
- (4) Option exercisable on 4/02/2004
- (5) Option is currently exercisable.
- (6) Performance share units will be earned on the earlier of 12/31/04 (unless employment terminates) or the date of change-in-control with the ultimate payout in the range of 0% to 125% of the number of units granted based upon the Company's relative total shareholder return compared to peer companies and absolute total shareholder return over the performance period.

Page 3 of 3